Maprotiline in affective illness: Plasma concentration and clinical response

doi:10.1016/0165-0327(83)90007-1

Journal of Affective Disorders

Volume 5, Issue 2, May 1983, Pages 147-154

https://doi.org/10.1016/0165-0327(83)90007-1 Get rights and content

Abstract

Twenty patients suffering from endogenous depression were treated with maprotiline for 4 weeks. Blood samples were collected at weekly intervals and severity of depression assessed using the Hamilton Depression Rating Scale. No simple relationship between plasma maprotiline concentration and amelioration score was observed at week 3 (r_s=0.25) or week 4 (r_s=-0.05). No significant difference in plasma concentrations between responders and non-responders was observed at week 4. Maprotiline was effective as an antidepressant in some patients.

References (23)

J. Angst et al.
Blood levels and clinical effects of maprotiline
T.A. Betts et al.
Epileptic fits as a probable side effect of amitriptyline
Lancet
(1968)
G.D. Burrows et al.
Plasma concentration of nortriptyline and clinical response in depressive illness
Lancet
(1972)
B.J. Carroll et al.
Sequential comparison of L-tryptophan with ECT in severe depression
Lancet
(1970)
A. Coppen et al.
A double-blind comparison of lithium carbonate and maprotiline in the prophylaxis of the affective disorders
Brit. J. Psychiat.
(1976)
A. Delini-Stula
The pharmacology of ludiomil
C. Fensbo
A clinical trial of nortriptyline and maprotiline with cardiovascular monitoring and serum level estimations
R. Fischbach
Maprotiline in adult depressed patients
Arzneim-Forsch.
(1979)
K.J. Hall et al.
Maprotiline hydrochloride and grand-mal seizures
Brit. Med. J.
(1980)
M. Hamilton
A rating scale for depression
J. Neurol. Neurosurg. Psychiat.
(1960)

A.M. Jukes

Maprotiline (Ludiomil) — Side effects and overdosage

J. Int. Med. Res.

(1975)

Cited by (5)

Assay for maprotiline in human serum with improved sensitivity and selectivity
1994, Journal of Chromatography B: Biomedical Sciences and Applications
The use of a photoreactor and fluorescence detection enables measurement of the tetracyclic antidepressant drug 3-(9,10-dihydro-9,10-ethanoanthracene-9-yl)-N-methylpropylamine (maprotiline) with a sensitivity of 100 pg/ml serum. This detection system is highly specific and enables the measurement of very low concentrations in the presence of high concentrations of other drugs that are often found in patient samples. The mean free portions of maprotiline and desmethylmaprotiline were found to be 2.2% and 1.5%, respectively.
Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects
1993, European Neuropsychopharmacology
We examined the relationship between plasma concentrations of specific acting antidepressants (fluvoxamine/maprotiline) and clinical improvement as well as the impact of the magnitude of the plasma concentration of these antidepressants on side effects. Patients (32 patients with major depression) were treated within a double-blind parallel trial for four weeks and plasma concentrations were obtained before, on days 8 and 28 of the trial. Although there was a fixed-flexible dosage design it was apparent that 16 patients (89%) of the fluvoxamine group and all patients of the maprotiline group received a dosage between 200 and 300 mg/day in the last week of the trial. Plasma concentrations (mean ± SD μg/l) of fluvoxamine were 125 ± 91 and 142 ± 108 on days 8 and 28, respectively and the range of fluvoxamine plasma concentrations on day 28 was from 20 to 417 μg/l. Plasma concentrations (mean ± SD μg/l) of maprotiline were 146 ± 62 and 202 ± 134 on days 8 and 28, respectively and the range of maprotiline plasma concentration on day 28 was from 12 to 428 μg/l. There was no linear relationship between plasma concentrations of both antidepressants (fluvoxamine/maprotiline) and oral dosage. Whereas there was no correlation between fluvoxamine concentration and clinical response there was a tendency that higher maprotiline concentrations were associated with a better antidepressive efficacy at the end of the trial. Higher concentrations of fluvoxamine as well as of maprotiline were significantly (P < 0.05) associated with more side effects.
Clinical effect of maprotiline on elderly depression associated with blood concentration
2006, Chinese Journal of Clinical Rehabilitation
Serum Levels of Maprotiline and Its Adverse Effects on Depressed Patients
1987, Psychiatry and Clinical Neurosciences
Plasma levels of maprotiline and zimelidine and their relationship to clinical response in depressed patients
1986, Therapeutic Drug Monitoring

View full text

Maprotiline in affective illness: Plasma concentration and clinical response

Abstract

Blood levels and clinical effects of maprotiline

Epileptic fits as a probable side effect of amitriptyline

Lancet

Plasma concentration of nortriptyline and clinical response in depressive illness

Lancet

Sequential comparison of L-tryptophan with ECT in severe depression

Lancet

A double-blind comparison of lithium carbonate and maprotiline in the prophylaxis of the affective disorders

Brit. J. Psychiat.

The pharmacology of ludiomil

A clinical trial of nortriptyline and maprotiline with cardiovascular monitoring and serum level estimations

Maprotiline in adult depressed patients

Arzneim-Forsch.

Maprotiline hydrochloride and grand-mal seizures

Brit. Med. J.

A rating scale for depression

J. Neurol. Neurosurg. Psychiat.

Maprotiline (Ludiomil) — Side effects and overdosage

J. Int. Med. Res.